Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related NVS
5 Biotechs With Catalysts Coming This Week
Novartis Completes Divestiture of Influenza Vaccines Business to CSL Limited for $275M
Premarket Biotech Digest: My Investment Strategy, Geron Updates, Regeneron Earnings (Seeking Alpha)
Related ZIOP
Ziopharm Oncology Downgraded By BMO As 'Questions Persist'
Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares
The Vetr community has downgraded $ZIOP to 3-Stars (Vetr)

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

Jul 2015Leerink SwannMaintainsOutperform
Jun 2015Bryan GarnierUpgradesNeutralBuy
Mar 2015NatixisUpgradesNeutralBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (IEX + NVS)

Get Benzinga's Newsletters